Zelnorm Can Cause Heart Problems, Including Heart Attack and Stroke

Jean Martin
Attorney
(866) 735-1102 Ext 367
Visit Jean Martin on Avvo
Posted by Jean MartinJune 27, 2008 5:17 PM

Zelnorm is a drug to treat Irritable Bowel Syndrome (IBS) in women. On March 30, 2007 , the FDA ordered that manufacturer Novartis stop selling Zelnorm due to an increased risk of serious heart problems. Women who used Zelnorm suffered an alarming high number of heart attack, stroke, irregular heart beat, angina, and serious chest pains, which sometimes signaled a “silent” heart attack. Users of Zelnorm received no warnings of these serious side effects until the FDA ordered Zelnorm to be withdrawn from the market.

0 Comments

Have an opinion about this post? Please consider leaving a comment or subscribing to the feed to have future articles delivered to your feed reader.

Comments for this article are closed.

Subscribe to InjuryBoard Wilmington

InjuryBoard Wilmington RSS Feeds

Keep up with the latest updates using your favorite RSS reader

Injury Board Wilmington is brought to you by Shipman & Wright

Legal Assistance Center

More Info
Shipman & Wright 866-735-1102 Ext. 367 www.shipmanlaw.com
google
Personal Injury Lawyers Serving: Wilmington, Burgaw, Carolina Beach, Jacksonville, Leland, Shallotte, Whiteville, Kings Grant, Masonboro, Murraysville, Myrtle Grove, Oak Island, Ogden, Piney Green, Seagate, Silver Lake, Wallace, Wrightsboro, Boiling Spring Lakes, Ocean Isle, Laurinburg, Elizabethtown, Hampstead, Topsail Island
575 Military Cutoff RoadSuite 106, Wilmington, North Carolina 28405 [ Show Map ]
Better Business Bureau Accredited Business Confidential

Your question will be referred to an attorney near you. If your question is of a legal nature, then by submitting this form you agree you are not forming a formal attorney / client relationship. Read our full privacy policy.

Looking for an InjuryBoard attorney closer to home? Click here.

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address